Evaluation of Antiplatelet/Anticoagulant Use and Prognosis in Primary Thrombophilia Patients with COVID-19

Objective: This study is aimed to investigate the relationship between inherited thrombophilia and COVID-19 symptoms and the outcomes of treatment strategies. Materials and Methods: This descriptive and retrospective study included patients who were followed up for thrombophilia in a training and research hospital. Data from 121 patients who had COVID-19 infection and those who met the inclusion criteria were collected through retrospective examination of medical records and telephone interviews using a data collection form developed by the researchers. The data obtained from the study was evaluated using descriptive and comparative statistical methods. Results: Among the patients diagnosed with COVID-19, 11.6% had severe clinical presentations requiring intensive care support. During COVID-19 infection, mostly no drug was preferred for treatment (51.2%), and the most preferred drug was acetylsalicylic acid (ASA) (33.1%). A total of 13 thromboembolic events occurred in 12 patients who were included in the study during and after COVID-19 infection. No thromboembolic events occurred in patients using warfarin or new-generation oral anticoagulants during COVID-19. There was no significant difference in thromboembolism complications among patients who did not use any medication, those who used ASA/clopidogrel, and those who used low molecular weight heparin during COVID-19 infection. The most common gene mutation in the study was plasminogen activator inhibitor-1 (PAI-1) mutation, and there was no statistically significant difference between PAI-1 gene mutation and new thrombotic events (p=0.988). Conclusion: COVID-19 infection was found to cause bilateral lung involvement with diffuse microthrombi in patients with genetic thrombophilia. No new thromboembolic events occurred in patients with thrombophilia using warfarin or new-generation oral anticoagulants.